© 1999 American Heart Association, Inc.
Original Contributions |
The Role of Alpha and Beta Platelet-Derived Growth Factor Receptor in the Vascular Response to Injury in Nonhuman Primates
From COR Therapeutics Inc (N.A.G., O.M., A.H., V.R., L.J.F.), South San Francisco; Department of Molecular and Experimental Medicine (J.A.K.), Scripps Research Institute, LaJolla, Calif; and Division of Hematology-Oncology, Department of Medicine (M.M.H.M., A.B.K., J.N.W., S.R.H.) and Department of Surgery (C.C.), Yerkes Regional Primate Research Center, Emory University, Atlanta, Ga.
Correspondence to Stephen R. Hanson, PhD, 1639 Pierce Dr, Room 1129 Woodruff Memorial Bldg, Emory University, Atlanta, GA, 30322. E-mail shanson{at}emory.edu
Abstract—Restenosis remains a significant clinical problem associated with mechanical interventional procedures for arterial revascularization or repair, including coronary angioplasty and stenting. Studies with rodents have established that platelet-derived growth factor (PDGF), a potent chemotactic and mitogenic agent for vascular smooth muscle cells, is a key mediator of lesion formation after vascular injury. To further explore this hypothesis in a more clinically relevant model, neutralizing monoclonal antibodies (mAbs) were used to examine the effect of selective inhibition of alpha or beta PDGF receptor (PDGFR) on neointima formation in nonhuman primates. Carotid arteries were injured by surgical endarterectomy and femoral arteries by balloon catheter dilatation. Immunostaining revealed that both injuries induced cell proliferation and the upregulation of beta PDGFR but not alpha PDGFR. By 7 days after injury, beta PDGFR staining was limited to the luminal region of the media, the small areas of neointima, and the adventitia. Nearly all bromodeoxyuridine-positive cells were found in these regions as well. After 30 days, a concentric neointima that stained strongly for beta PDGFR had formed in the carotid and femoral arteries. Treatment of baboons with anti-beta PDGFR mAb 2A1E2 for 6 days after injury reduced the carotid artery and femoral artery lesion sizes by 37% (P<0.05) and 48% (P<0.005), respectively, when measured at 30 days. Under the same conditions, treatment with anti-alpha PDGFR mAb 2H7C5 had no effect. These findings suggest that PDGF mediates neointima formation through the beta PDGFR, and that antagonism of this pathway may be a promising therapeutic strategy for reducing clinical restenosis.
Key Words: angioplasty • endarterectomy • tyrosine kinase • smooth muscle cell • monoclonal antibody
This article has been cited by other articles:
 |
|
 |
|
  K. J. Ho, C. D. Owens, T. Longo, X. X. Sui, C. Ifantides, and M. S. Conte C-reactive protein and vein graft disease: evidence for a direct effect on smooth muscle cell phenotype via modulation of PDGF receptor-{beta} Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1132 - H1140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zhuang, Q. Pu, B. Ceacareanu, Y. Chang, M. Dixit, and A. Hassid Chronic insulin treatment amplifies PDGF-induced motility in differentiated aortic smooth muscle cells by suppressing the expression and function of PTP1B Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H163 - H173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Andrae, R. Gallini, and C. Betsholtz Role of platelet-derived growth factors in physiology and medicine Genes & Dev., May 15, 2008; 22(10): 1276 - 1312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Szabo, J. Laki, H. O. Madsen, E. Dosa, Z. Prohaszka, S. Rugonfalvi-Kiss, M. Kokai, G. Acsadi, I. Karadi, L. Entz, et al. Early Rise in Serum VEGF and PDGF Levels Predisposes Patients With a Normal MBL2 Genotype to Restenosis After Eversion Endarterectomy Stroke, August 1, 2007; 38(8): 2247 - 2253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kappert, J. Paulsson, J. Sparwel, O. Leppanen, C. Hellberg, A. Ostman, and P. Micke Dynamic changes in the expression of DEP-1 and other PDGF receptor-antagonizing PTPs during onset and termination of neointima formation FASEB J, February 1, 2007; 21(2): 523 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kawai-Kowase and G. K. Owens Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells Am J Physiol Cell Physiol, January 1, 2007; 292(1): C59 - C69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lassila, T. J. Allen, Z. Cao, V. Thallas, K. A. Jandeleit-Dahm, R. Candido, and M. E. Cooper Imatinib Attenuates Diabetes-Associated Atherosclerosis Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 935 - 942. [Abstract] [Full Text]
|
|
|
|
|
|
S. Q. Liu, C. Tieche, D. Tang, and P. Alkema Pattern formation of vascular smooth muscle cells subject to nonuniform fluid shear stress: role of PDGF-{beta} receptor and Src Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H1081 - H1090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kozaki, W. E. Kaminski, J. Tang, S. Hollenbach, P. Lindahl, C. Sullivan, J.-C. Yu, K. Abe, P. J. Martin, R. Ross, et al. Blockade of Platelet-Derived Growth Factor or Its Receptors Transiently Delays but Does Not Prevent Fibrous Cap Formation in ApoE Null Mice Am. J. Pathol., October 1, 2002; 161(4): 1395 - 1407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. X. Rong, J. W. Berman, M. B. Taubman, and E. A. Fisher Lysophosphatidylcholine Stimulates Monocyte Chemoattractant Protein-1 Gene Expression in Rat Aortic Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., October 1, 2002; 22(10): 1617 - 1623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Nathe, J. Deou, B. Walsh, B. Bourns, A. W. Clowes, and G. Daum Interleukin-1{beta} Inhibits Expression of p21(WAF1/CIP1) and p27(KIP1) and Enhances Proliferation in Response to Platelet-Derived Growth Factor-BB in Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., August 1, 2002; 22(8): 1293 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Horvath, F. G.P. Welt, M. Nedelman, P. Rao, and C. Rogers Targeting CCR2 or CD18 Inhibits Experimental In-Stent Restenosis in Primates: Inhibitory Potential Depends on Type of Injury and Leukocytes Targeted Circ. Res., March 8, 2002; 90(4): 488 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhan, S. Kim, H. Yasumoto, M. Namba, H. Miyazaki, and H. Iwao Effects of Dominant-Negative c-Jun on Platelet-Derived Growth Factor-Induced Vascular Smooth Muscle Cell Proliferation Arterioscler. Thromb. Vasc. Biol., January 1, 2002; 22(1): 82 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Yu, N. A. Lokker, S. Hollenbach, M. Apatira, J. Li, A. Betz, D. Sedlock, S. Oda, Y. Nomoto, K. Matsuno, et al. Efficacy of the Novel Selective Platelet-Derived Growth Factor Receptor Antagonist CT52923 on Cellular Proliferation, Migration, and Suppression of Neointima following Vascular Injury J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1172 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sano, T. Sudo, M. Yokode, T. Murayama, H. Kataoka, N. Takakura, S. Nishikawa, S.-I. Nishikawa, and T. Kita Functional Blockade of Platelet-Derived Growth Factor Receptor-{beta} but Not of Receptor-{alpha} Prevents Vascular Smooth Muscle Cell Accumulation in Fibrous Cap Lesions in Apolipoprotein E-Deficient Mice Circulation, June 19, 2001; 103(24): 2955 - 2960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Leppanen, N. Janjic, M.-A. Carlsson, K. Pietras, M. Levin, C. Vargeese, L. S. Green, D. Bergqvist, A. Ostman, and C.-H. Heldin Intimal Hyperplasia Recurs After Removal of PDGF-AB and -BB Inhibition in the Rat Carotid Artery Injury Model Arterioscler. Thromb. Vasc. Biol., November 1, 2000; 20 (11): e89 - e95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Topper Genes, Matrix, and Restenosis Arterioscler. Thromb. Vasc. Biol., October 1, 2000; 20(10): 2173 - 2174. [Full Text] [PDF]
|
|
|
|
|
|
M. G. Davies, E. L. Owens, D. P. Mason, H. Lea, P. K. Tran, S. Vergel, S. A. Hawkins, C. E. Hart, and A. W. Clowes Effect of Platelet-Derived Growth Factor Receptor-{alpha} and -{beta} Blockade on Flow-Induced Neointimal Formation in Endothelialized Baboon Vascular Grafts Circ. Res., April 14, 2000; 86(7): 779 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Horvath, F. G.P. Welt, M. Nedelman, P. Rao, and C. Rogers Targeting CCR2 or CD18 Inhibits Experimental In-Stent Restenosis in Primates: Inhibitory Potential Depends on Type of Injury and Leukocytes Targeted Circ. Res., March 8, 2002; 90(4): 488 - 494. [Abstract] [Full Text] [PDF]
|
|